Horizon Therapeutics Inks Option Agreement For Atopic Dermatitis Candidate

  • Q32 Bio and Horizon Therapeutics plc HZNP entered into a collaboration and option agreement to develop ADX-914 for autoimmune diseases.
  • ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. 
  • Q32 has recently completed a biomarker-enabled Phase 1 study characterizing pharmacokinetics, pharmacodynamics, and safety of ADX-914 that demonstrated pharmacological effect on T cells in healthy volunteers.
  • Q32 expects to initiate a Phase 2 trial in atopic dermatitis later this year and is planning to initiate a Phase 2 trial in a second autoimmune disease next year.
  • Horizon will fund development through the completion of the two Phase 2 trials of ADX-914, with Q32 being operationally responsible for the conduct of all program-related activities. 
  • Horizon will receive an option to acquire the ADX-914 program, exercisable through the completion of the Phase 2 trials.
  • During the option period, Q32 will receive $55 million, of which Horizon expects to recognize as R&D expenses approximately $32.5 million in Q3 of 2022 and the remainder in 2023.
  • If Horizon exercises the option, Q32 may be eligible to receive up to an additional $645 million in milestone payments.
  • Price Action: HZNP shares are down 2.13% at $66.03 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!